Phase 4 N=437 Fibrinogen in Haemorrhage of Delivery
Post-Partum Hemorrhage
Primary: Failure Rate of PPH Management — 75; 80; 92; 92 Participants — p=0.9563
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=91 Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Relapsed or Refractory Chronic Lymphocytic Leukemia · Relapsed or Refractory Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) — 80 Participants — p=<0.0001
Phase 3 N=1,062 Adaptive COVID-19 Treatment Trial (ACTT)
COVID-19
Primary: Time to Recovery — 15; 10 Days — p=<0.001
Phase 2 N=111 A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Phase 1 N=16 Flortaucipir PET Imaging in Subjects With FTD
Frontotemporal Dementia
Primary: Qualitative Evaluation of Flortaucipir PET Scans — 0; 0; 13 Participants
Phase 2 N=227 A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change From Baseline in BCVA Letter Score at Week 24, in Treatment-Naive Participants — 10.3; 11.7; 13.9 BCVA letters — p=0.37
Phase 4 N=53 Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
Cognition in Schizophrenia
Primary: Neuropsychological Measures for MATRICS — 20.82; 18.03; 25.43; 11.64 score on a scale
N/A N=8,164 VITATOPS: A Study of VITAmins TO Prevent Stroke
Stroke · Transient Ischemic Attack
Primary: Non-fatal Stroke, Non-fatal Myocardial Infarction or Death Due to Vascular Causes — 616; 678 Participants — p=0.05
Phase 2 N=188 Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
Malaria
Primary: Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) — 11.1; 0; 0; 0…
Phase 2 N=75 Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)
PTSD
Primary: Clinician Administered PTSD Scale (CAPS) Score — -21.1; -16.7 score on a scale — p=0.442
N/A N=4,559 CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI
Traumatic Brain Injury
Primary: Glasgow Outcome Scale - Extended (GOSE) at 6 Months — 2419; 207; 665; 1547 Participants — p=<0.0001
Phase 4 N=1,487 EVOLVE Short DAPT Study
Coronary Artery Disease
Primary: Number of Participants Who Experienced Death or Myocardial Infarction (MI) — 84 Participants
Phase 3 N=32 Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)
Hypersensitivity
Primary: Cumulative Irritation Total (CIT) Score — 0.0; 20.0; 0.0 Score on a scale
N/A N=14 Acceptance and Commitment Therapy for Tobacco Cessation Among Psychiatric Partial Hospital Patients
Tobacco Smoking · Psychiatric Disorder · Psychiatric Hospitalization
Primary: Feasibility of Recruitment: Proportion of Smokers Seen During the Partial Hospital Visit Who Enroll in the Study — 17 Participants
N/A N=21 Comparison of Post Tooth Extraction Healing Using Different Xenograft Materials
Alveolar Bone Loss
Primary: Percent New Bone Formation — 41; 25; 26 percentage of new bone formation